🚨Update: 2025 ATA recommendations for RAI activity, RAI activity for the intermediate risk (both low- and high- group) is lower than the 2015 ATA (30-100 mCi vs >30-150 mCi). Final RAI activity by MDT is recommended. #ata #thyroid #2025ata #nuclearmedicine

🚨Update: 2025 ATA recommends FDG PET/CT for high-risk DTC with elevated serum Tg and negative RAI scan, a prognostic tool, and evaluation of treatment response following systemic or local therapy #ata #thyroid #thyroidcancer

Join millions who have switched to Grok.

🚨Update: 2025 ATA Proposed criteria for RAIR DTC. There are TWO criteria which patients are unlikely to have clinical benefit from additional RAIT (no uptake on post-tx scan and/or disease progression <6 mo after RAIT) #thyroid #nuclearmedicine #ata #DTC

Apart from cell surface of prostate adenoCA, PSMA expression has also been found in neovasculature of various conditions, e.g. other tumors (HCC, RCC, …), infection, and inflammation. #psma #petct #prostatecancer #nuclearmedicine

According to a meta-analysis including 29 studies, mpMRI had higher sensitivity than PSMA PET for detection of ECE and SVI with similar specificity. PSMA PET has a role as a combined imaging for T-staging in prostate cancer. #prostatecancer #psma #petct

False-negative PSMA PET imaging could be due to PC with neuroendocrine differentiation, low serum PSA level, small metastatic LN (size <4 mm), high physiologic uptake (bladder, liver), etc.

F-18 FES PET/CT can be used as a biomarker for PFS and OS in recurrent or MBC patients who received endocrine therapy + CDK4/6 inhibitor. For further details: #breastcancer #estrogen #breastimaging #petct

The 1st day of the BNMS Annual Spring Meeting 2025 at SEC, Glasgow. Focusing on PET vs SPECT MPI, PSMA theranostics, Medical physics, and Patient inclusivity and engagement #BNMSnews #BNMS #nuclearmedicine #Glasgow

According to the recent review article published in Endocrine Practice, TRAb is used to determine whether the long-term MMI should be continued in patients with Graves disease or not. #aace #gravesdisease #thyroid #mmi #hyperthyroidism

According to NCCN Guidelines 2025, DXA should be done in most of the patients with prostate cancer at ADT initiation. Then, DXA should be done q 1-2 years depending on FRAX. DXA at 1 year is also recommended for patients receiving antiresorptive therapy. #dxa

Sestamibi-avid renal mass: oncocytoma >>> renal cell carcinoma? High Sen and Spec (89%) but the level of evidence is still low. For further details: #snmmi #jnm #eanm #urology

Postoperative RAI treatment and TSH suppression are not indicated for patients with NIFTP. However, the follow-up protocol is still debated. Is it should be monitored in the same way as low-risk PTC? #thyroidtumor #I131 #thyroiddisease #snmmi #eanm #eta

RT @dr_coops: Great summary re: avoiding false positive PSMA pitfalls from Irene Burger #APCCCDiagnostics25

According to the VISION and TheraP studies, SUVmean at the baseline PSMA PET/CT is the strong biomarker to predict OS and response after LuPSMA therapy. #psma #prostatecancer #petct

How many cycles of Lu-177 PSMA therapy in patients with prostate cancer in your theranostic center?.

If toxicity occurs during Lu-177 PSMA-RLT, the interval between the cycle can be extended for 2 weeks, up to 10-week interval. The activity can be reduced by 20%, without re-escalation. #psma #psmatherapy #lu177 #prostatecancer

Three future directions of PSMA-RLT including using in earlier stage of prostate cancer, combination with other treatments, and new PSMA-targeting agents. Here are the lists of clinical trials.

According to the phase III RCT VISION, patients with PSMA-negative lesion were ineligible for the trial. However, an osteoblastic lesion without soft tissue formation with low PSMA uptake was not considered a PSMA-negative lesion. #psma #petct #prostatecancer

When to perform the post-therapy scan after Lu-177 PSMA administration in your routine practice?.

Improvement of cytopenia has been reported several times after LuPSMA therapy in patients with superscan.